Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astellas Pharma Inc (ALPMY)

Astellas Pharma Inc (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 20,720,640
  • Shares Outstanding, K 1,809,663
  • Annual Sales, $ 10,620 M
  • Annual Income, $ 113,000 K
  • 60-Month Beta 0.37
  • Price/Sales 1.85
  • Price/Cash Flow 9.91
  • Price/Book 1.93
Trade ALPMY with:
  • Price/Earnings ttm 24.74
  • Earnings Per Share ttm 0.46
  • Most Recent Earnings $0.24 on 08/01/24
  • Next Earnings Date 11/06/24
  • Annual Dividend & Yield 0.15 (1.33%)
  • Most Recent Dividend 0.152 on 03/26/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.01
  • Growth Rate Est. (year over year) +9,990,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.2100 +3.48%
on 10/02/24
12.9900 -10.70%
on 09/06/24
-0.7200 (-5.84%)
since 09/03/24
3-Month
9.7100 +19.46%
on 07/05/24
13.1400 -11.72%
on 08/29/24
+1.7950 (+18.31%)
since 07/03/24
52-Week
9.1500 +26.78%
on 04/16/24
14.0300 -17.32%
on 10/11/23
-1.9200 (-14.20%)
since 10/03/23

Most Recent Stories

More News
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years

The multibillionaire's portfolio features some moneymaking ideas.

ALPMY : 11.6000 (+1.31%)
GOOG : 167.21 (-0.06%)
GOOGL : 165.86 (unch)
AMZN : 181.96 (-1.52%)
MSFT : 416.54 (-0.14%)
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

AMGN : 317.48 (-0.70%)
BMY : 54.20 (+0.82%)
LLY : 885.55 (-0.62%)
XLV : 151.52 (-0.90%)
HZNP : 116.30 (+0.04%)
JNJ : 160.50 (-0.42%)
MRK : 110.18 (-1.70%)
NVS : 113.77 (-0.61%)
NVO : 115.08 (-1.20%)
XPH : 44.03 (-0.63%)
ALPMY : 11.6000 (+1.31%)
Why Shares of Annexon Are Plummeting Thursday

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

ISEE : 39.95 (+0.38%)
APLS : 28.06 (-1.47%)
ALPMY : 11.6000 (+1.31%)
ANNX : 6.21 (-3.27%)
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

These three biotech stocks were on the volatile side today.

APLS : 28.06 (-1.47%)
TGTX : 22.19 (-0.85%)
VKTX : 64.11 (-0.90%)
ISEE : 39.95 (+0.38%)
ALPMY : 11.6000 (+1.31%)
Pfizer buys Seagen for $43B, boosts access to cancer drugs

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue

ALPMY : 11.6000 (+1.31%)
$SPX : 5,699.94 (-0.17%)
$DOWI : 42,011.59 (-0.44%)
$IUXX : 19,793.34 (-0.05%)
PFE : 28.34 (-0.94%)
Got $1,000? Here's a Dirt-Cheap Big Pharma Stock to Buy

Pfizer should remain a pharma powerhouse long after the COVID-19 pandemic comes to an end.

PFE : 28.34 (-0.94%)
BNTX : 119.80 (+0.67%)
JNJ : 160.50 (-0.42%)
ALPMY : 11.6000 (+1.31%)
BMY : 54.20 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment...

See More

Key Turning Points

3rd Resistance Point 11.7333
2nd Resistance Point 11.7067
1st Resistance Point 11.6533
Last Price 11.6000
1st Support Level 11.5733
2nd Support Level 11.5467
3rd Support Level 11.4933

See More

52-Week High 14.0300
Fibonacci 61.8% 12.1658
Last Price 11.6000
Fibonacci 50% 11.5900
Fibonacci 38.2% 11.0142
52-Week Low 9.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar